Core Thesis - SkyWater Technology, Inc. (SKYT) is positioned for significant growth, targeting revenue increases from approximately $342 million in 2024 to over $600 million by 2026, with a long-term goal of reaching $1.7 billion by 2035 [2] Company Overview - SkyWater operates as a pure-play technology foundry in the semiconductor sector, providing development, manufacturing, and packaging services in the U.S. [2] - The company is focusing on becoming a foundational partner for next-generation computing, particularly in superconducting integrated circuits and photonics [3] Competitive Advantage - SkyWater's "Technology as a Service" (TaaS) model differentiates it from traditional contract manufacturers, allowing for co-development of chips within its fabrication environment [3] - The company's "Trusted" status with the U.S. Department of Defense creates a strong competitive moat, particularly for government and defense-related programs [4] Financial Performance - Operating leverage is beginning to emerge, with GAAP gross margins reaching 24% in Q3 2025, and margins are expected to expand as the business transitions from R&D-heavy programs to higher-volume wafer services [4] - Strategic investments, such as the acquisition of Fab 25 for approximately $93 million, have significantly increased revenue capacity [5] Market Position and Future Outlook - The company is capital intensive but is well-positioned to benefit from government initiatives like the CHIPS and Science Act, which could lead to a significant valuation rerating [5] - SkyWater's stock price has appreciated by approximately 148.6% since previous bullish coverage, indicating strong market confidence in its long-term revenue scaling and operating leverage [7]

We came across a bullish thesis on Biohaven Ltd. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on BHVN. Biohaven Ltd.'s share was trading at $11.54 as of February 18th. 25 Best Work-Life Balance Jobs to Enjoy Life Photographee.eu/Shutterstock.com Biohaven Ltd. is a clinical-stage biotechnology company targeting large global markets with significant unmet needs across neurology, immunology, and oncology, with lead programs such as its Kv7 activator franchise rep ...

Core Thesis - Biohaven Ltd. is positioned as a promising investment opportunity due to its potential blockbuster programs and a robust pipeline, with shares trading at $11.54 as of February 18th [1][3]. Company Overview - Biohaven Ltd. is a clinical-stage biotechnology company focusing on neurology, immunology, and oncology, with significant unmet needs in these areas [3]. - The company's lead programs, particularly its Kv7 activator franchise, could justify a substantial increase in market capitalization from approximately $1.4 billion if one or two Phase 3 trials succeed [3]. Long-term Vision - The company aims to evolve into a multi-franchise, platform-driven biopharma utilizing proprietary technologies, which could create a sustainable innovation engine [4]. - A single late-stage success could validate the broader platform and enhance the company's competitive advantage, which is supported by proven execution and a diversified pipeline [4]. Financial Position - Biohaven remains loss-making with negative free cash flow, typical for high-growth biotech firms, indicating that returns are heavily reliant on clinical milestones [6]. - The company has implemented a 60% reduction in R&D spending to extend its financial runway, while also securing a $600 million non-dilutive agreement to strengthen its financing position [5]. Market Sentiment and Risks - Investor confidence has been pressured by fragmentation across therapeutic areas and a recent setback with a Complete Response Letter, contributing to stock volatility [5]. - The market currently discounts the potential for a five-fold valuation increase to about $7 billion due to execution risks and pipeline uncertainties, creating a high-volatility but asymmetric long-term investment opportunity [6].

We came across a bullish thesis on Fortis Inc. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on FTS. Fortis Inc.'s share was trading at $56.33 as of February 18th. FTS’s trailing and forward P/E were 22.70 and 21.41 respectively according to Yahoo Finance. energy Energy transmission lines. Photo by Snapwire on Pexels Fortis Inc. is positioned as a regulated electric and gas utility delivering predictable, rate-base-driven growth rather than hyper-growth. The co ...

Berkshire Hathaway Inc. To My Fellow Berkshire Shareholders, Warren Buffett is arguably the greatest investor of all time, with generations benefiting from his investment acumen. He has also been a remarkable CEO, executing his vision of building a great insurance business since the acquisition of National Indemnity in 1967, and deploying the float to make successful investments across major sectors of the economy, concentrating in the U.S. (To Warren's great frustration, this letter begins with these obser ...

We came across a bullish thesis on Intellia Therapeutics, Inc. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on NTLA. Intellia Therapeutics, Inc.'s share was trading at $12.48 as of February 18th. Best Innovative Stocks To Buy Now Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. NTLA represents a potentially transformative opportunity in the biotechnology space, anchored by its ...

Core Thesis - Intellia Therapeutics, Inc. (NTLA) is positioned as a transformative player in the biotechnology sector, focusing on curative genome editing treatments through in-vivo CRISPR technology [2][3] Company Overview - Intellia is a clinical-stage gene editing company that has demonstrated systemic CRISPR efficacy in humans, targeting diseases such as ATTR amyloidosis and hereditary angioedema with one-time treatments [2] - The company is among the first to explore a new drug category termed "genomic surgery," supported by partnerships with major pharmaceutical companies like Regeneron, Novartis, and Vertex [3] Market Opportunity - The market potential for Intellia is substantial, with ATTR and HAE representing multi-billion-dollar markets, and one-time therapy pricing expected to range from $500,000 to $2 million per patient [4] - Gross margins for these therapies could exceed 80%, with potential expansion into oncology and CNS disorders [4] Financial Position - Intellia maintains a strong balance sheet with over $700 million in cash and a low-debt structure, providing a financial runway of 2–3 years without the need for additional financing [5] - The company has significant institutional backing, including major biotech funds and Regeneron, although stock volatility may occur in risk-off market conditions [5] Value Creation Path - Upcoming catalysts for value creation include Phase 2/3 data for NTLA-2001 (ATTR), Phase 2 data for NTLA-2002 (HAE), FDA regulatory feedback, and potential commercial filings [6] - The bull case suggests that multiple approved drugs could validate Intellia's platform, potentially driving a market capitalization of $20–30 billion [7] Comparative Analysis - Intellia's in-vivo CRISPR work and its optionality across monogenic diseases are highlighted as key differentiators compared to other companies in the sector, such as CRISPR Therapeutics AG [8]

We came across a bullish thesis on Omnicell, Inc. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on OMCL. Omnicell, Inc.'s share was trading at $38.61 as of February 18th. OMCL’s trailing P/E was 912.50 according to Yahoo Finance. Why Impact Biomedical Inc. (IBO) Surged On Thursday? Elena Pavlovich/Shutterstock.com Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies th ...

Core Thesis - Omnicell, Inc. is positioned for transformative growth by shifting from hardware-driven revenue to a software- and services-led model, with a current share price of $38.61 and a trailing P/E of 912.50 [1][2] Group 1: Revenue and Growth Strategy - The company is currently generating approximately $1.18 billion in revenue and aims to double sales to around $2.4 billion by 2031, primarily through high-margin SaaS offerings and Expert Services [3] - Strategic acquisitions, such as ANiGENT in October 2025, are expanding Omnicell's footprint in drug diversion detection, enhancing recurring revenue streams [3] Group 2: Market Position and Competitive Advantage - Long-term growth is anticipated from the vision of an "Autonomous Pharmacy," where AI and robotics manage all medication handling, addressing healthcare labor shortages expected by 2030 [4] - Omnicell's competitive advantage includes high switching costs, over 900 patents, and a large installed base that supports proprietary AI capabilities, although competition from companies like Becton Dickinson necessitates ongoing innovation [4] Group 3: Financial Outlook and Valuation - As recurring revenue approaches nearly 50% of total revenue, margins are projected to expand from the low teens to the mid-20s, supported by strategic acquisitions and debt reduction [5] - The bull case suggests a potential fivefold increase in valuation if Annual Recurring Revenue (ARR) exceeds $1.5 billion, with a market re-rating from a traditional medical equipment multiple to a Healthcare IT multiple [6]

We came across a bullish thesis on VICI Properties Inc. on Compounding Dividends’s Substack. In this article, we will summarize the bulls’ thesis on VICI. VICI Properties Inc.'s share was trading at $29.86 as of February 17th. VICI’s trailing and forward P/E were 11.14 and 10.14 respectively according to Yahoo Finance. REIT Stocks Northstar Realty Finance NRF g0d4ather / shutterstock.com VICI Properties (VICI) is a real estate investment trust that owns one of the largest portfolios of market-leading ga ...